TSHA vs SRPT vs RARE

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). Analysts rate Taysha Gene Therapies, Inc. (TSHA) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Taysha Gene Therapies, Inc.

(TSHA) delivered a total return of -68. 5%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: SRPT returned +18. 0% versus TSHA's -72. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc.

(RARE) is the lower-risk stock at 1. 42β versus Taysha Gene Therapies, Inc. 's 2. 06β — meaning TSHA is approximately 45% more volatile than RARE relative to the S&P 500. On balance sheet safety, Taysha Gene Therapies, Inc. (TSHA) carries a lower debt/equity ratio of 7% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). On earnings-per-share growth, the picture is similar: Ultragenyx Pharmaceutical Inc. grew EPS 7. 3% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, TSHA leads at 57. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sarepta Therapeutics, Inc.

(SRPT) is the more profitable company, earning -32. 5% net margin versus -1115. 3% for Taysha Gene Therapies, Inc. — meaning it keeps -32. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRPT leads at -29. 9% versus -1130. 6% for TSHA. At the gross margin level — before operating expenses — TSHA leads at 88. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RARE: 97.

1% to $51. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Taysha Gene Therapies, Inc. (TSHA) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RARE: -59. 4%, TSHA: -72. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.